The bivariate NRIP1/ZEB2 RNA marker permits non-invasive presymptomatic screening of pre-eclampsia

Manders, Vera; Visser, Allerdien; Keijser, Remco; Min, Naomi; Poutsma, Ankie; Mulders, Joyce; Berkmortel, Tarah van den; Hortensius, Marjolein; Jongejan, Aldo; Pajkrt, Eva; Sistermans, Erik A.; Sie, Daoud; Best, Myron G.; Würdinger, Tom; Boer, Marjon A. de; Afink, Gijs B.; Oudejans, Cees B.M.

doi:10.1038/s41598-020-79008-4

Cited by 6 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its function is not completely understood, but it is known that NRIP1 can corepress transcription factors as thyroid hormone receptor (TR), estrogen-related receptor (EER), and E2F transcription factor 1 (E2F1) [47]. Dysregula-tion of this gene has been observed in different human pathological conditions, such as in cancer patients and in preeclamptic pregnancies [48,49]. circNRIP1 has been found differentially expressed in several types of tumor tissues, such as gastric cancer, cervical cancer, and ovarian cancer [50][51][52][53].…”

Section: Discussionmentioning

confidence: 99%

The Analysis of Platelet-Derived circRNA Repertoire as Potential Diagnostic Biomarker for Non-Small Cell Lung Cancer

D’Ambrosi

Visser

Antunes-Ferreira

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Tumor-educated Platelets (TEPs) have emerged as rich biosources of cancer-related RNA profiles in liquid biopsies applicable for cancer detection. Although human blood platelets have been found to be enriched in circular RNA (circRNA), no studies have investigated the potential of circRNA as platelet-derived biomarkers for cancer. In this proof-of-concept study, we examine whether the circRNA signature of blood platelets can be used as a liquid biopsy biomarker for the detection of non-small cell lung cancer (NSCLC). We analyzed the total RNA, extracted from the platelet samples collected from NSCLC patients and asymptomatic individuals, using RNA sequencing (RNA-Seq). Identification and quantification of known and novel circRNAs were performed using the accurate CircRNA finder suite (ACFS), followed by the differential transcript expression analysis using a modified version of our thromboSeq software. Out of 4732 detected circRNAs, we identified 411 circRNAs that are significantly (p-value < 0.05) differentially expressed between asymptomatic individuals and NSCLC patients. Using the false discovery rate (FDR) of 0.05 as cutoff, we selected the nuclear receptor-interacting protein 1 (NRIP1) circRNA (circNRIP1) as a potential biomarker candidate for further validation by reverse transcription–quantitative PCR (RT-qPCR). This analysis was performed on an independent cohort of platelet samples. The RT-qPCR results confirmed the RNA-Seq data analysis, with significant downregulation of circNRIP1 in platelets derived from NSCLC patients. Our findings suggest that circRNAs found in blood platelets may hold diagnostic biomarkers potential for the detection of NSCLC using liquid biopsies.

show abstract

Section: Discussionmentioning

confidence: 99%

The Analysis of Platelet-Derived circRNA Repertoire as Potential Diagnostic Biomarker for Non-Small Cell Lung Cancer

D’Ambrosi

Visser

Antunes-Ferreira

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…ZEB2 upregulates superoxide dismutase 2 (SOD2) expression and controls mitochondrial stress through sirtuin 3 (SIRT3)‐mediated autophagy [51]. Plasma nuclear receptor interacting protein 1 (NRIP1)‐to‐ZEB2 ratio is significantly upregulated during the first trimester of pregnancy in women with PE compared with controls [52].…”

Section: Effects Of Molecules Related To Pas Development On Mitochond...mentioning

confidence: 99%

Current understanding of the pathogenesis of placenta accreta spectrum disorder with focus on mitochondrial function

Kobayashi,

Matsubara,

Yoshimoto

et al. 2024

J of Obstet and Gynaecol

View full text Add to dashboard Cite

AimThe refinement of assisted reproductive technology, including the development of cryopreservation techniques (vitrification) and ovarian stimulation protocols, makes frozen embryo transfer (FET) an alternative to fresh ET and has contributed to the success of assisted reproductive technology. Compared with fresh ET cycles, FET cycles were associated with better in vitro fertilization outcomes; however, the occurrence of pregnancy‐induced hypertension, preeclampsia, and placenta accreta spectrum (PAS) was higher in FET cycles. PAS has been increasing steadily in incidence as a life‐threatening condition along with cesarean rates worldwide. In this review, we summarize the current understanding of the pathogenesis of PAS and discuss future research directions.MethodsA literature search was performed in the PubMed and Google Scholar databases.ResultsRisk factors associated with PAS incidence include a primary defect of the decidua basalis or scar dehiscence, aberrant vascular remodeling, and abnormally invasive trophoblasts, or a combination thereof. Freezing, thawing, and hormone replacement manipulations have been shown to affect multiple cellular pathways, including cell proliferation, invasion, epithelial‐to‐mesenchymal transition (EMT), and mitochondrial function. Molecules involved in abnormal migration and EMT of extravillous trophoblast cells are beginning to be identified in PAS placentas. Many of these molecules were also found to be involved in mitochondrial biogenesis and dynamics.ConclusionThe etiology of PAS may be a multifactorial genesis with intrinsic predisposition (e.g., placental abnormalities) and certain environmental factors (e.g., defective decidua) as triggers for its development. A distinctive feature of this review is its focus on the potential factors linking mitochondrial function to PAS development.

show abstract

“…SERPINB9 plays a role in cytotoxic protection of natural killer cells [85,86] and in cancer [87], and it has previously been shown to be significantly dysregulated in preeclampsia at the transcriptional level in placenta [64,67]. NRIP1 was also found to be upregulated in the placenta [88] and plasma [89] in preeclampsia patients, and it has been suggested as an RNA biomarker but not validated at the protein level. QPCT was found to be upregulated in a microarray study of preeclamptic placenta but significant dysregulation was not be confirmed in RT-qPCR experiments [38].…”

Section: Biomarkers In Preeclampsiamentioning

confidence: 99%

Biomarker screening in preeclampsia: an RNA-sequencing approach based on data from multiple studies

Rezk¹,

Grasegger²,

Brandstetter³

et al. 2022

Journal of Hypertension

View full text Add to dashboard Cite

Objective:Biomarkers have become important in the prognosis and diagnosis of various diseases. High-throughput methods, such as RNA sequencing facilitate the detection of differentially expressed genes (DEGs), hence potential biomarker candidates. Individual studies suggest long lists of DEGs, hampering the identification of clinically relevant ones. Concerning preeclampsia – a major obstetric burden with high risk for adverse maternal and/or neonatal outcomes – limitations in diagnosis and prediction are still important issues. We, therefore, developed a workflow to facilitate the screening for biomarkers.Methods:On the basis of the tool DESeq2, a comprehensive workflow for identifying DEGs was established, analyzing data from several publicly available RNA-sequencing studies. We applied it to four RNA-sequencing datasets (one blood, three placenta) analyzing patients with preeclampsia and normotensive controls. We compared our results with other published approaches and evaluated their performance.Results:We identified 110 genes that are dysregulated in preeclampsia, observed in at least three of the studies analyzed, six even in all four studies. These included FLT-1, TREM-1, and FN1, which either represent established biomarkers at protein level, or promising candidates based on recent studies. For comparison, using a published meta-analysis approach, 5240 DEGs were obtained.Conclusion:This study presents a data analysis workflow for preeclampsia biomarker screening, capable of identifying promising biomarker candidates, while drastically reducing the numbers of candidates. Moreover, we were also able to confirm its performance for heart failure. This approach can be applied to additional diseases for biomarker identification, and the set of DEGs identified in preeclampsia represents a resource for further studies.

show abstract

The bivariate NRIP1/ZEB2 RNA marker permits non-invasive presymptomatic screening of pre-eclampsia

Cited by 6 publications

References 22 publications

The Analysis of Platelet-Derived circRNA Repertoire as Potential Diagnostic Biomarker for Non-Small Cell Lung Cancer

The Analysis of Platelet-Derived circRNA Repertoire as Potential Diagnostic Biomarker for Non-Small Cell Lung Cancer

Current understanding of the pathogenesis of placenta accreta spectrum disorder with focus on mitochondrial function

Biomarker screening in preeclampsia: an RNA-sequencing approach based on data from multiple studies

Contact Info

Product

Resources

About